As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.
CROS NT Ltd, the UK branch of CROS NT, sees the acquisition as an important part of the overall group strategy. The deal adds additional resources to the existing group in the UK and will provide a new headquarters for the UK company in Maidenhead, close to London. MDSL International has built a reputation for providing strong consultancy and project work coupled with excellent customer service.
Andrew MacGarvey, CEO and President of CROS NT, said, "I am delighted to expand the UK operation through this acquisition. We are adding a highly experienced team to the business and further diversifying our customer base - both important objectives of the CROS NT Group. We will move our UK Headquarters to Maidenhead, giving us a great location in terms of on-going recruitment and access to our customers given its proximity to London. Coming shortly after our acquisition of Stat-Tech Services in the USA, this deal demonstrates our commitment to place expertise close to our customers and to grow to meet the increasing demand for our services."
Edmund Otun, the founder of MDSL International, said, "I am pleased to have concluded the deal with CROS NT. Being part of a larger entity allows us to provide additional resources to our existing clients - something they have been asking for. CROS NT has a very strong management team, with great experience in the CRO business. I will remain with the company providing consultancy for emerging companies seeking advice on getting their products to market or securing licencing deals."
Jo Marshall, MDSL International Managing Director, who will become the UK Country Manager for CROS NT Ltd added, "I am excited by this opportunity and looking forward to working with the CROS NT team. In addition to giving us greater critical mass here in the UK, this deal will give our existing customers access to the CROS NT technology portfolio which includes several Electronic Data Capture (EDC) platforms, a Clinical Trial Management System (CTMS), and electronic Patient Recorded Outcomes (ePRO) solutions."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.